Add to ORKGInhibition of soluble fibrinogen binding to activated platelets represents the target of pharmacologic approach with antagonists of the glycoprotein IIb/IIIa (GPIIb/IIIa) complex. In this study we assessed the effects of abciximab, a recombinant chimeric Fab fraction of the antibody against GPIIb/IIIa, on several markers of platelet activation
Soon after identification of the platelet membrane glycoprotein (GP) IIb/IIIa, it has become a targe...
In normal haemostasis, key receptors on human blood platelets, glycoprotein (GP)Ibα of the GPIb-IX-V...
AbstractNew strategies for profound inhibition of platelet activity at the injured coronary plaque f...
In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividu...
AbstractDespite the success of abciximab in preventing ischemic events after percutaneous coronary i...
Background—Tests developed to monitor glycoprotein (GP) IIb/IIIa blockade do not properly reflect pl...
The human glycoprotein (GP)IIb/IIIa belongs to a large family of cation-dependent adhesion molecules...
BACKGROUND: The best method for measuring the degree of platelet inhibition with glycoprotein (GP) I...
Platelets play a pivotal role in the pathogenesis of coronary artery disease and myocardial infarcti...
As the glycoprotein GPIIb/IIIa receptor is the final common pathway in platelet aggregation, antagon...
Background: New antiplatelet agents that provide greater, more consistent inhibition of the platelet...
BACKGROUND: The ability of abciximab to prevent fibrinogen binding to activated platelets indicates ...
Aims: To compare three glycoprotein IIb/IIIa receptor antagonists (GPIs) in terms of platelet inhibi...
AbstractOBJECTIVESThe goal of this study was to evaluate platelet function and to preliminarily asse...
In addition to inhibition of platelet aggregation, GPIIb-IIIa antagonists may reduce thrombotic even...
Soon after identification of the platelet membrane glycoprotein (GP) IIb/IIIa, it has become a targe...
In normal haemostasis, key receptors on human blood platelets, glycoprotein (GP)Ibα of the GPIb-IX-V...
AbstractNew strategies for profound inhibition of platelet activity at the injured coronary plaque f...
In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividu...
AbstractDespite the success of abciximab in preventing ischemic events after percutaneous coronary i...
Background—Tests developed to monitor glycoprotein (GP) IIb/IIIa blockade do not properly reflect pl...
The human glycoprotein (GP)IIb/IIIa belongs to a large family of cation-dependent adhesion molecules...
BACKGROUND: The best method for measuring the degree of platelet inhibition with glycoprotein (GP) I...
Platelets play a pivotal role in the pathogenesis of coronary artery disease and myocardial infarcti...
As the glycoprotein GPIIb/IIIa receptor is the final common pathway in platelet aggregation, antagon...
Background: New antiplatelet agents that provide greater, more consistent inhibition of the platelet...
BACKGROUND: The ability of abciximab to prevent fibrinogen binding to activated platelets indicates ...
Aims: To compare three glycoprotein IIb/IIIa receptor antagonists (GPIs) in terms of platelet inhibi...
AbstractOBJECTIVESThe goal of this study was to evaluate platelet function and to preliminarily asse...
In addition to inhibition of platelet aggregation, GPIIb-IIIa antagonists may reduce thrombotic even...
Soon after identification of the platelet membrane glycoprotein (GP) IIb/IIIa, it has become a targe...
In normal haemostasis, key receptors on human blood platelets, glycoprotein (GP)Ibα of the GPIb-IX-V...
AbstractNew strategies for profound inhibition of platelet activity at the injured coronary plaque f...